, Volume 40, Issue 1, pp 52–57 | Cite as

Mangiferin Inhibits IL-1β-Induced Inflammatory Response by Activating PPAR-γ in Human Osteoarthritis Chondrocytes

  • Yanlong QuEmail author
  • Li Zhou
  • Chunlei Wang


Inflammation has been reported to play critical roles in the development of osteoarthritis. In the present study, we investigated whether mangiferin (MFN) had anti-inflammatory effects in IL-1β-stimulated human osteoarthritis chondrocytes. The cells were treated with various concentrations of MFN in the presence or absence of IL-1β. The production of MMP-1, MMP-3, PGE2, and NO was measured in this study. The expression of NF-kB and PPAR-γ was detected by western blot analysis. MFN inhibited IL-1β-induced inflammatory mediators PGE2 and NO production. MFN also inhibited IL-1β-induced MMP1 and MMP3 production. IL-1β-induced NF-kB activation was significantly inhibited by MFN. In addition, MFN was found to up-regulate the expression of PPAR-γ in human osteoarthritis chondrocytes. PPAR-γ inhibitor GW9662 significantly reversed the anti-inflammatory effects of MFN. These results suggest that MFN inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes by activating PPAR-γ.


mangiferin osteoarthritis chondrocyte IL-1β PPAR-γ 



This research project was supported by the National Natural Science Foundation of China (30500508) and the Natural Science Foundation of Heilongjiang Provinces (D201112).

Compliance with Ethical Standards

The study was in accordance with the Declaration of Helsinki and Tokyo.


  1. 1.
    Martin, J.A., and J.A. Buckwalter. 2002. Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology 3: 257–264.CrossRefPubMedGoogle Scholar
  2. 2.
    Bonnet, C., and D. Walsh. 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology 44: 7–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Van der Kraan, P., and W. Van den Berg. 2012. Chondrocyte hypertrophy and osteoarthritis: Role in initiation and progression of cartilage degeneration? Osteoarthritis and Cartilage 20: 223–232.CrossRefPubMedGoogle Scholar
  4. 4.
    Abramson, S.B., M. Attur, A.R. Amin, and R. Clancy. 2001. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Current Rheumatology Reports 3: 535–541.CrossRefPubMedGoogle Scholar
  5. 5.
    Ahmed, S., A. Rahman, A. Hasnain, M. Lalonde, V.M. Goldberg, and T.M. Haqqi. 2002. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radical Biology and Medicine 33: 1097–1105.CrossRefPubMedGoogle Scholar
  6. 6.
    Tak, P.P., and G.S. Firestein. 2001. NF-kB: A key role in inflammatory diseases. The Journal of Clinical Investigation 107: 7–11.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Roman-Blas, J., and S. Jimenez. 2006. NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 14: 839–848.CrossRefPubMedGoogle Scholar
  8. 8.
    Chen, Y.-C., L.-L. Yang, and T.J. Lee. 2000. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kB activation. Biochemical Pharmacology 59: 1445–1457.CrossRefPubMedGoogle Scholar
  9. 9.
    Bhatia, H.S., E. Candelario-Jalil, A.C. de Oliveira, O.A. Olajide, G. Martinez-Sanchez, and B.L. Fiebich. 2008. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Archives of Biochemistry and Biophysics 477: 253–258.CrossRefPubMedGoogle Scholar
  10. 10.
    Jang, J.H., K.H. Lee, H.K. Jung, M.O. Sim, T.M. Kim, K.W. Woo, B.K. An, J.H. Cho, and H.W. Cho. 2016. Anti-inflammatory effects of 6′-O-acetyl mangiferin from Iris rossii Baker via NF-kappab signal blocking in lipopolysaccharide-stimulated RAW 264.7 cells. Chemico-Biological Interactions 257: 54–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Pan, C.W., Z.Z. Pan, J.J. Hu, W.L. Chen, G.Y. Zhou, W. Lin, L.X. Jin, and C.L. Xu. 2016. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. European Journal of Pharmacology 770: 85–91.CrossRefPubMedGoogle Scholar
  12. 12.
    He, L., X. Peng, J. Zhu, X. Chen, H. Liu, C. Tang, Z. Dong, F. Liu, and Y. Peng. 2014. Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. American Journal of Nephrology 40: 441–450.CrossRefPubMedGoogle Scholar
  13. 13.
    Dou, W., J. Zhang, G. Ren, L. Ding, A. Sun, C. Deng, X. Wu, X. Wei, S. Mani, and Z. Wang. 2014. Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-kappaB and MAPK signaling inactivation. International Immunopharmacology 23: 170–178.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cheng, A.W., T.V. Stabler, M. Bolognesi, and V.B. Kraus. 2011. Selenomethionine inhibits IL-1beta inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) expression in primary human chondrocytes. Osteoarthritis and Cartilage 19: 118–125.CrossRefPubMedGoogle Scholar
  15. 15.
    Ma, C., Y. Zhang, Y.Q. Li, C. Chen, W. Cai, and Y.L. Zeng. 2015. The role of PPARgamma in advanced glycation end products-induced inflammatory response in human chondrocytes. PLoS One 10, e0125776.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Piao, T., Z. Ma, X. Li, and J. Liu. 2015. Taraxasterol inhibits IL-1beta-induced inflammatory response in human osteoarthritic chondrocytes. European Journal of Pharmacology 756: 38–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Goldring, S.R., and M.B. Goldring. 2004. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clinical Orthopaedics and Related Research 427: S27–S36.CrossRefGoogle Scholar
  18. 18.
    Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354–366.PubMedGoogle Scholar
  19. 19.
    Park, K.S. 2016. Catalpol reduces the production of inflammatory mediators via PPAR-gamma activation in human intestinal Caco-2 cells. Journal of Natural Medicines 70: 620–626.CrossRefPubMedGoogle Scholar
  20. 20.
    Chang, C.Z., S.C. Wu, and A.L. Kwan. 2015. Glycyrrhizin attenuates proinflammatory cytokines through a peroxisome proliferator-activated receptor-gamma-dependent mechanism and experimental vasospasm in a rat model. Journal of Vascular Research 52: 12–21.CrossRefPubMedGoogle Scholar
  21. 21.
    Bo, Q.L., Y.H. Chen, Z. Yu, L. Fu, Y. Zhou, G.B. Zhang, H. Wang, Z.H. Zhang, and D.X. Xu. 2016. Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation. Molecular and Cellular Endocrinology 423: 51–59.CrossRefPubMedGoogle Scholar
  22. 22.
    Song, Y., H.F. Zhao, J.Y. Liu, C. Fang, and R.Y. Miao. 2016. Effects of citral on lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells. Inflammation 39: 663–671.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of OrthopedicsThe First Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations